News

News2020-07-17T11:41:26-04:00
Oct 192020

Arizona State University/Halberd Initiate Patent Application for Unique New Engineered Class of Covid-19 Antibody

October 19th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , |

Updated 12:30PM Jackson Center, PA, October 19, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19.  The discovery is the result of Halberd’s research in conjunction with Arizona State University’s Dr. Qiang “Shawn” Chen, utilizing Halberd’s intellectual property created by Mitchel S. Felder, MD.  Halberd and ASU have begun the process of filing the first of multiple planned joint patent applications for ...

Oct 132020

Arizona State University/Halberd Develop Antibody Against Covid-19

October 13th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , |

Jackson Center, PA, October 13, 2020 – Halberd Corporation (OTC PINK: "HALB") reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19.  The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate.  In addition, the researchers have sent for synthesis, genes for the creation of new, unique monoclonal antibodies against the SARS-CoV-2 Spike ...

Oct 82020

Halberd Corporation CEO Update Letter – October, 2020

October 8th, 2020|Categories: Featured, Investor News|Tags: , , , , |

Greetings From The CEO And Staff At Halberd Corporation! (OTC-PINK: HALB) This initial CEO Letter reflects a summary of major accomplishments since I began my tenure at Halberd Corporation.  Going forward, I intend to provide update letters to our shareholders and the public on a quarterly basis. A LOOK BACK Since I began at Halberd back in May, I have been working on assembling a talented team of technical and business leaders (who, like me, ...

Oct 12020

Halberd COVID-19 Preventative Nasal Spray Provisional Patent Application Filed

October 1st, 2020|Categories: Featured, Investor News, News|

Jackson Center, PA, October 1, 2020 – Halberd Corporation (OTC-PINK: "HALB") announced they have obtained world-wide license to a provisional patent application covering a nasal spray to be used as a prevention measure against coronavirus.  The provisional patent, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” was filed recently with the U.S. Patent and Trademark Office by its inventor, Mitchell S. Felder, MD. The nasal spray is intended to be used as a ...

Sep 282020

Arizona State University/Halberd Pursue Nasal Spray As Covid-19 Preventative/Treatment Based On Children’s Natural Immunity

September 28th, 2020|Categories: Featured, Investor News, News|Tags: , , , , , , , , , |

Jackson Center, PA, September 28, 2020 – Children are far less susceptible than adults to the Coronavirus (1, 2).  Halberd Corporation’s (OTC PINK: "HALB") scientists have determined the reason may be that adults have far more Angiotensin-Converting Enzyme 2 (ACE2) receptors in nasal membrane epithelial cells.  ACE2 (3) is a membrane protein expressed in many organs such as nasal and lung epithelial cells. Traditionally, ACE 2 has a key role in the blood pressure regulatory ...

Sep 242020

Arizona State University/Halberd Corp. Covid-19 R&D Program Rapid Diagnostic Test / Treatment

September 24th, 2020|Categories: Featured, Investor News, News|Tags: , , , |

Jackson Center, PA, September 24, 2020 – Halberd Corporation (OTC PINK: "HALB") clarifies next steps in their unique research with Arizona State University.  Halberd directed their research program to focus on that element of Covid-19 which makes the disease most contagious -- the spike antigen. ASU investigators have projected the production of the coronavirus spike antigen within the next two weeks. The next steps for the ASU/Halberd program involve identification of an antibody conjugate which ...

Go to Top